

REMARKS

As required by 37 C.F.R. §1.125(b), Applicants have enclosed a substitute specification in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated October 10, 2002. As to the substitute specification, Applicants submit that no new matter was added. Enclosed is a marked up version showing all the changes to the specification of record in red. In addition, the specification in clean form without markings as to the amended material is also enclosed.

In the substitute specification, Applicants have inserted all the appropriate sequence identification numbers.

As stated in 37 C.F.R. §1.82(d), "Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing", reference must be made to the sequence by the use of a sequence identifier." Further, "Sequence identifiers can also be used to discuss and/or claim parts or fragments of a properly presented sequence." MPEP §2422.03. Thus, in the Tables, Applicants have inserted language that uses sequence identifiers to discuss fragments of presented sequences.

In the unlikely event that the patent office determines that extensions and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the assistant commissioner to charge the cost of such petitions and/or fees due to our deposit account no. 03-1952 under order no. 511582000100. The assistant commissioner is not authorized to charge the cost of the issue fee to the deposit account.

Respectfully submitted,

Dated: December 10, 2002

By:

A handwritten signature in dark ink, appearing to read 'K. Murashige', followed by the number '(29,128)' in parentheses.

Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125